Interview with Juergen Knackmuss, Chairman, GPHF
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
Address: Walter-Benjamin-Platz 6, D-10629 Berlin,Germany
Tel: +49 30 327787-0
The firm has a nationwide presence. Since an increasing number of medical mandates – for instance, in the field of law governing drugs and medical devices – are not confined to national boundaries, we work with law firms based in other European countries which specialize in similar fields. We primarily work with our EuMedLex partners. The company advises on all branches of medical law and also on related aspects pertaining to public law, corporate law and competition law.They offer competence and experience in the field of medical law, ensuring that clients can base their personal and entrepreneurial decisions on a reliable juridical foundation. The firm is independent, pointing out legal boundaries to clients – and looking for ways to achieve their goals in spite of these. The company is multidisciplinary: The special fields of medical law will direct a client to appropriately proven attorneys in the law firm. Nonetheless daily technical discussions with each other always keep the lawyers abreast of the latest developments in the fields.
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
See our Cookie Privacy Policy Here
